evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

262 questions · 309 findings · 35 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 66 · 21.4%GRADE not reported 46 · 14.9%Very low 85 · 27.5%Low 60 · 19.4%Moderate 38 · 12.3%High 14 · 4.5%

Rituximab vs other disease‐modifying treatments

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Rituximab vs other disease‐modifying treatments

Natalizumab · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).

2 findings from 1 review

Rituximab vs other disease‐modifying treatments

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Conventional restorative treatment with compomer vs Other network treatments

Treatment success rate · Primary teeth with dentin caries lesions on occlusal surfaces

CRT with compomer ranked first for treatment success in the occlusal-surface network (low certainty).

1 finding from 1 review

Silver diamine fluoride twice annually vs Other network treatments

Caries lesion arrestment · Primary teeth with dentin caries lesions on occlusal and smooth surfaces

Silver diamine fluoride twice annually ranked first for caries lesion arrestment in the occlusal- and smooth-surface network (moderate certainty).

1 finding from 1 review

Hall technique vs Other network treatments

Treatment success rate · Primary teeth with dentin caries lesions on occlusoproximal surfaces

The Hall technique ranked first for treatment success in the occlusoproximal-surface network (low certainty).

1 finding from 1 review

Anticholinergic medication vs other treatments

Adverse effect: any adverse effects · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether anticholinergic medication changes adverse effect: any adverse effects compared with other treatments (very low certainty).

1 finding from 1 review

Anticholinergic medication vs other treatments

Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).

1 finding from 1 review

Anticholinergic medication vs other treatments

Tardive dyskinesia: No clinically important improvement · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether anticholinergic medication changes tardive dyskinesia: Not improved to a clinically important extent compared with other treatments (very low certainty).

1 finding from 1 review